HIMS

Hims Hers Health Inc
NYSEHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

Key Statistics

Market Cap
$6.85B
P/E Ratio
—
EPS
$-0.64
Beta
2.43
52W High
$52.41
52W Low
$13.74
50-Day MA
$29.40
200-Day MA
$27.32
Dividend Yield
—
Profit Margin
-5.51%
Forward P/E
73.53
PEG Ratio
2.59

About Hims Hers Health Inc

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$2.58B
Gross Profit (TTM)$1.79B
EBITDA$-10.18M
Operating Margin-12.80%
Return on Equity-32.00%
Return on Assets-2.21%
Revenue/Share (TTM)$11.29
Book Value$1.39
Price-to-Book20.44
Price-to-Sales (TTM)2.66
EV/Revenue2.843
EV/EBITDA205.86
Quarterly Earnings Growth (YoY)-17.40%
Quarterly Revenue Growth (YoY)38.20%
Shares Outstanding$224.94M
Float$213.75M
% Insiders4.95%
% Institutions70.99%

Historical Volatility

HV 10-Day
81.69%
HV 20-Day
68.66%
HV 30-Day
58.62%
HV 60-Day
86.58%
HV Rank
14.3%

Volatility is currently expanding

Analyst Ratings

Consensus ($31.15 target)
2
Strong Buy
1
Buy
11
Hold
1
Strong Sell

Latest News

Kaplan Fox Alerts Hims & Hers Health, Inc. (HIMS) Investors of a Securities Class Action Filed in Federal Court - Deadline is November 2, 2026

New York, New York--(Newsfile Corp. - October 16, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.

Newsfile Corp10/16/2026Neutral
Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, Oct. 16, 2026 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct. Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.

PRNewsWire10/16/2026Neutral
Kaplan Fox Announces a Securities Class Action Against Hims & Hers Health, Inc. (NYSE: HIMS) – Lead Plaintiff Deadline is November 2, 2026

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.

GlobeNewsWire10/16/2026Neutral
HIMS EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between August 4, 2025 and July 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 16, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (""Hims" or the "Company") (NYSE: HIMS) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Newsfile Corp10/16/2026Neutral
HIMS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - HIMS

New York, New York--(Newsfile Corp. - October 15, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline. SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp10/16/2026Neutral
Hims & Hers Health (HIMS) Alert: Securities Fraud Class Action Filed, Investors Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline

San Francisco, California--(Newsfile Corp. - October 15, 2026) - Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business misconduct. Hagens Berman, which is actively investigating the alleged claims, encourages HIMS investors who suffered substantial losses to submit your losses now.

Newsfile Corp10/15/2026Neutral
Kaplan Fox Encourages Hims & Hers Health, Inc. (HIMS) Investors to Learn About the Securities Class Action Ahead of the November 2, 2026 Deadline

New York, New York--(Newsfile Corp. - October 15, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us.

Newsfile Corp10/15/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HIMS and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 10/17/2026